Skip to main content
Premium Trial:

Request an Annual Quote

Buying Bayer Rights, Celera Axes Axys Collaboration

NEW YORK, Oct. 8 - Celera Genomics has bought from Bayer all rights to preclinical research held under an existing collaboration between the two companies. In the process, Celera has untied a research partnership in place since before the Applera unit bought Axys Pharmaceuticals last year.

 

Celera has acquired rights to all compounds, study data, and relevant IP related to the use of the compounds in all fields, including the primary area of application, which in this case are potential asthma therapies.

 

Financial details were not disclosed.

 

"We plan to obtain pilot scale quantities of these compounds and to complete additional IND-enabling toxicology and safety evaluations in the coming months," Robert Booth, Celera's senior vice president of research and development, said in a statement this morning.

 

The companies agreed to terminate the collaborative research-and-license agreement penned in November 1994 by Arris Pharmaceutical, a predecessor of Axys Pharmaceuticals, a company Celera bought in November 2001. The company operates as Celera South San Francisco.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.